Reviva Q1 2025 net loss $6.4M; cash $5.3M; OLE trial complete with 446 patients

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Net loss $6.4M ($0.13/sh) vs $7.4M ($0.25/sh) in Q1 2024; cash & equivalents $5.3M as of Mar 31, 2025 down from $13.5M at Dec 31, 2024.
Long-term OLE trial of brilaroxazine completed: 446 participants, 156 completed 12 months, 301 completed 6 months.
Full OLE data (safety, efficacy, biomarkers) expected Q2 2025; registrational Phase 3 RECOVER-2 initiation expected mid-2025 subject to financing.
NDA submission for brilaroxazine in schizophrenia targeted for Q4 2026; IND for psoriasis liposomal-gel formulation expected later in 2025.
Company to present late-breaking poster on RECOVER 12-month OLE data at ASCP meeting on May 28, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.